Lipoprotein-Inspired Nanoparticles for Cancer Theranostics

• Published in: Accounts of chemical research 2011-10, Vol.44 (10), p.1105-1113
• Main Authors: Ng, Kenneth K, Lovell, Jonathan F, Zheng, Gang
• Format: Article
• Language: English
• Subjects: Animals; Biological Transport; Biomimetics - methods; Cancer; Cell Line, Tumor; Diagnostic systems; Heart diseases; Humans; Lipoproteins; Lipoproteins - chemistry; Lipoproteins - metabolism; Lipoproteins - therapeutic use; Maneuvers; Molecular Targeted Therapy; Nanoparticles; Nanoparticles - chemistry; Nanoparticles - therapeutic use; Nanostructure; Neoplasms - diagnosis; Neoplasms - metabolism; Neoplasms - therapy; Receptors
• ISSN: 0001-4842; 1520-4898
• DOI: 10.1021/ar200017e

Over hundreds of millions of years, animals have evolved endogenous lipoprotein nanoparticles for shuttling hydrophobic molecules to different parts of the body. In the last 70 years, scientists have developed an understanding of lipoprotein function, often in relationship to lipid transport and heart disease. Such biocompatible, lipid–protein complexes are also ideal for loading and delivering cancer therapeutic and diagnostic agents, which means that lipoprotein and lipoprotein-inspired nanoparticles also offer opportunities for cancer theranostics. By mimicking the endogenous shape and structure of lipoproteins, the nanocarrier can remain in circulation for an extended period of time, while largely evading the reticuloendothelial cells in the body’s defenses. The small size (less than 30 nm) of the low-density (LDL) and high-density (HDL) classes of lipoproteins allows them to maneuver deeply into tumors. Furthermore, lipoproteins can be targeted to their endogenous receptors, when those are implicated in cancer, or to other cancer receptors. In this Account, we review the field of lipoprotein-inspired nanoparticles related to the delivery of cancer imaging and therapy agents. LDL has innate cancer targeting potential and has been used to incorporate diverse hydrophobic molecules and deliver them to tumors. Nature’s method of rerouting LDL in atherosclerosis provides a strategy to extend the cancer targeting potential of lipoproteins beyond its narrow purview. Although LDL has shown promise as a drug nanocarrier for cancer imaging and therapy, increasing evidence indicates that HDL, the smallest lipoprotein, may also be of use for drug targeting and uptake into cancer cells. We also discuss how synthetic HDL-like nanoparticles, which do not include human or recombinant proteins, can deliver molecules directly to the cytoplasm of certain cancer cells, effectively bypassing the endosomal compartment. This strategy could allow HDL-like nanoparticles to be used to deliver drugs that have increased activity in the cytoplasm. Lipoprotein nanoparticles have evolved to be ideal delivery vehicles, and because of that specialized function, they have the potential to improve cancer theranostics.